

HEPATOBIILIARY DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
 ROOM: NAME: ROSSETTI
 SATURDAY APRIL 28, 2018, 3:00 PM – 4:00 PM

CO-CHAIRS : DR. JENNIFER KNOX AND DR. OLIVER BATHE
 SENIOR INVESTIGATOR: DR. CHRIS O'CALLAGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- *To interpret and address, through clinical and translational research, the disease burden associated with hepatobiliary malignancies in Canada.*
- *To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to hepatobiliary malignancies.*
- *To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to hepatobiliary malignancies.*
- *To interpret and apply new clinical trial methodologies in the field of clinical research in hepatobiliary malignancies.*

3:00 pm	Setting Strategic Plan	Dr. O. Bathe
	Active/Recently Closed Trials for Update	Dr. O. Bathe
3:20 pm	HE. 1: Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases	Dr. R. Wong
	Approved Trials in Development	
3:25 pm	BI. 3 Phase II/III Trial Comparing Acelarin plus Cisplatin to Gemcitabine Plus Cisplatin in First-Line Treatment of Locally Advanced or Metastatic Biliary Cancer	Dr. C. O'Callaghan
	New Concepts in Development	
3:35 pm	SWOG Gemcitabine and Capecitabine vs Capecitabine +/- Radiotherapy in R1 Resected Adjuvant Biliary Cancer	Dr. O. Bathe
3:45 pm	Sequential vs combination Immunotherapy and TKIs in HCC	Dr. V. Tam
3:55 pm	Intergroup Task Force Update	Dr. O. Bathe
4:00 pm	Meeting adjourned	